Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 August 2026. This shift reflects deteriorating technical indicators, subdued financial trends, expensive valuation metrics, and a decline in overall quality scores, signalling caution for investors amid challenging market conditions.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This change is underscored by a combination of bearish and neutral signals across key technical indicators, reflecting a complex market sentiment as the stock navigates recent price pressures and sector dynamics.

Gujarat Themis Biosyn Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent downgrade in daily price performance, key technical indicators such as MACD, RSI, and moving averages reveal a complex picture that investors should carefully analyse before making decisions.

Gujarat Themis Biosyn Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 July 2026, providing investors with the latest insights into its performance and outlook.

Gujarat Themis Biosyn Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators that suggest an improving outlook for this small-cap pharmaceutical player. Recent upgrades in technical grades and a 3.27% day gain underscore renewed investor interest, positioning the stock for potential further gains amid mixed sector dynamics.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in daily price performance, the company’s technical indicators reveal a cautiously optimistic outlook, prompting a reassessment of its market stance from Sell to Hold.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, upgrading its MarketsMOJO grade from Sell to Hold as of 23 June 2026. This change reflects improving technical indicators and a cautiously optimistic outlook despite a modest day decline of 2.28% to close at ₹392.50 on 29 June 2026.

The 50-day moving average has crossed above the 200-day moving average for Gujarat Themis Biosyn Ltd, signalling a golden cross on 25 Jun 2026. Yet, the stock declined 2.28% on the same day, while monthly technical indicators remain mildly bearish. This juxtaposition of signals calls for a detailed examination of the broader technical and fundamental context.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 23 June 2026. This change reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite recent quarterly setbacks, the company’s long-term market-beating returns and improving technical indicators have prompted a more favourable outlook.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently shifted its technical momentum from sideways to mildly bullish, reflecting a nuanced change in market sentiment. Despite a slight dip in the daily price, the stock’s weekly and monthly technical indicators present a mixed but cautiously optimistic outlook for investors.

Gujarat Themis Biosyn Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd has been downgraded from a Hold to a Sell rating as of 1 June 2026, reflecting a shift in technical indicators and valuation metrics despite its strong long-term returns. The company’s Mojo Score has declined to 42.0, with a corresponding Mojo Grade of Sell, driven primarily by deteriorating technical trends and concerns over flat recent financial performance.

Gujarat Themis Biosyn Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a nuanced outlook for investors as the stock navigates recent volatility.

Gujarat Themis Biosyn Ltd experienced a notable intraday decline on 29 May 2026, touching a low of Rs 400.5, down 7.61% from previous levels. The stock underperformed its sector and broader market indices amid widespread selling pressure and a bearish market environment.